Keros Therapeutics Inc Revenue Growth Rates (KROS), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Keros Therapeutics Inc   (NASDAQ: KROS)
 

KROS's Revenue Growth by Quarter and Year

Keros Therapeutics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/KROS/growth
https://api.csimarket.com/api/v1/companies/KROS/fundamentals
https://api.csimarket.com/api/v1/companies/KROS/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
KROS Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 40.01
2nd Quarter June 0.00
1st Quarter March 2.70
FY 42.71

KROSs Annual Revenue
Keros Therapeutics Inc 's Revenue in the fiscal year 2025 $ 268.93 millions
Keros Therapeutics Inc 's Revenue in the fiscal year 2024 $ 27.05 millions
Keros Therapeutics Inc 's Revenue in the fiscal year 2023 $ 14.91 millions
Keros Therapeutics Inc 's Revenue in the fiscal year 2022 $ 0.00 millions
Keros Therapeutics Inc 's Revenue in the fiscal year 2021 $ 20.10 millions




KROS Revenue third quarter 2026 Y/Y Growth Comment
Keros Therapeutics Inc reported Revenue surge of 88.72% year on year in the third quarter 2026, to $ 40.01 millions, this is lower than Keros Therapeutics Inc 's recent average Revenue surge of 589.14%.

Looking into third quarter 2026 results within Major Pharmaceutical Preparations industry 102 other companies have achieved higher Revenue growth. While Keros Therapeutics Inc ' s Revenue jump of 88.72% ranks overall at the positon no. 2034 in the third quarter 2026.


KROS Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 88.72 %
2nd Quarter June -
1st Quarter March -98.76 %
FY   -

Financial Statements
Keros Therapeutics Inc 's third quarter 2026 Revenue $ 40.01 millions KROS's Income Statement
Keros Therapeutics Inc 's third quarter 2025 Revenue $ 21.20 millions Quarterly KROS's Income Statement


KROS Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June -
1st Quarter March 592.31 %
FY (Year on Year)   -


Back to KROS Growth rate Comparisons >> Back to KROS Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #103
Healthcare Sector #312
Overall #2034

Revenue Y/Y Growth Statistics
High Average Low
861.27 % 589.14 % -82.25 %
(Jun 30 2025)   (Mar 31 2026)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #103
Healthcare Sector #312
Overall #2034
Revenue Y/Y Growth Statistics
High Average Low
861.27 % 589.14 % -82.25 %
(Jun 30 2025)   (Mar 31 2026)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Keros Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


KROS's III. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


KROS's III. Quarter Q/Q Revenue Comment


Keros Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025) 12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 0.00
Y / Y Revenue Growth (TTM) -
Year on Year Revenue Growth Overall Ranking # 31
Seqeuential Revenue Change (TTM) -
Seq. Revenue Growth (TTM) Overall Ranking # 2034


Cumulative Revenue growth Comment
Keros Therapeutics Inc realized trailing twelve months of $ 0 millions, in the Jun 30 2026, compare to Revenue of $ 252 millions a year ago.

Among companies within the Healthcare sector 10 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 23 to 31.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 103
Healthcare Sector # 11
Overall # 31

Revenue TTM Y/Y Growth Statistics
High Average Low
861.27 %
 589.14 %
-82.25 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 103
Sector # 312
S&P 500 # 2034
Cumulative Revenue growth Comment
Keros Therapeutics Inc realized trailing twelve months of $ 0 millions, in the Jun 30 2026, compare to Revenue of $ 252 millions a year ago.

Among companies within the Healthcare sector 10 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 23 to 31.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 103
Healthcare Sector # 11
Overall # 31

Revenue TTM Y/Y Growth Statistics
High Average Low
861.27 %
589.14 %
-82.25 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 103
Sector # 312
S&P 500 # 2034




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
KROS's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Neuraxis Inc 149.92%$ 149.922 millions
Pluri Inc 140.19%$ 140.190 millions
Camp4 Therapeutics Corporation138.87%$ 138.868 millions
Sonida Senior Living Inc 114.40%$ 114.402 millions
Verastem Inc 113.59%$ 113.592 millions
Hyperfine Inc 109.27%$ 109.270 millions
Pelthos Therapeutics Inc 107.87%$ 107.872 millions
Co diagnostics Inc 94.58%$ 94.580 millions
Autolus Therapeutics Plc94.57%$ 94.574 millions
Qt Imaging Holdings Inc exact Name Of Registrant As Specified In Its Charter _______________________93.02%$ 93.022 millions
Keros Therapeutics Inc 88.77%$ 88.766 millions
Profound Medical Corp 85.86%$ 85.857 millions
Vivosim Labs Inc 82.14%$ 82.143 millions
Syndax Pharmaceuticals Inc 81.59%$ 81.592 millions
Iovance Biotherapeutics inc 80.07%$ 80.074 millions
Rhythm Pharmaceuticals Inc 79.59%$ 79.594 millions
Omniab Inc 78.34%$ 78.339 millions
Aclarion Inc 78.09%$ 78.086 millions
Personalis Inc 76.59%$ 76.585 millions
Delcath Systems Inc 76.05%$ 76.047 millions
Mobia Medical Inc 73.28%$ 73.280 millions
Wave Life Sciences Ltd 72.95%$ 72.950 millions
Igc Pharma Inc 71.73%$ 71.728 millions
Phathom Pharmaceuticals Inc 71.14%$ 71.142 millions
Ptc Therapeutics inc 69.57%$ 69.571 millions
Seres Therapeutics Inc 68.95%$ 68.946 millions
Alamar Biosciences Inc 68.46%$ 68.458 millions
Carlsmed Inc 66.74%$ 66.736 millions
Corcept Therapeutics Inc63.97%$ 63.974 millions
Tarsus Pharmaceuticals Inc 63.92%$ 63.921 millions


About Keros Therapeutics Inc Revenue Growth Rates (KROS), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Keros Therapeutics Inc (CIK 1664710).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001664710-26-000066
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Keros Therapeutics Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.